As technology continues to evolve, bringing AI, advanced imaging, and novel sampling techniques into routine practice, the ...

A capsule-sponge test may help identify patients with Barrett’s esophagus who are at low risk for dysplasia or esophageal ...

The highest risk of high-grade dysplasia or cancer was seen for patients with both atypia and aberrant p53 (relative risk, 135.8 relative to the low-risk group). In the low-risk group, the prevalence ...

In adult patients with nondysplastic Barrett esophagus at last endoscopy, a subsequent capsule-sponge test can assist in identifying those at highest risk of dysplasia or cancer, according to a study ...

Patients with low-grade dysplasia have around a one in 10 chance of developing esophageal cancer, but this risk doubles to one in five for high-grade dysplasia.

The FDA has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

The FDA approved mitomycin intravesical solution (Zusduri) for patients with recurrent low-grade intermediate risk non–muscle-invasive bladder cancer (NMIBC).

Dysplasia can be caused by the chronic inflammation of IBD. Because they are precancerous, it's important to monitor and get them removed.

Testing for somatic genomic copy number alterations (CNAs) in ulcerative colitis patients with low-grade dysplasia was able to predict risk of advanced neoplasia more accurately than other ...

Castle Biosciences’ TissueCypher® test can offer patients with Barrett’s esophagus a clearer picture of their risk of developing esophageal cancer. Esophageal cancer is a killer. It’s the ...

The first-ever Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day is dedicated to raising awareness, providing resources, and advocating for more research into this rare and recurrent form of ...

Among those with BE with high-grade dysplasia, the AGA strongly recommends EET over surveillance. For patients with BE with low-grade dysplasia, the AGA suggests EET over surveillance.